tofacitinib Articles

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19 April 2013

Newly approved tofacitinib slows rheumatoid arthritis joint damage

24 January 2013

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

7 November 2012

Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021

16 September 2012

FDA puts back action date on Pfizer's tofacitinib by three months

22 August 2012

Pfizer RA drug candidate tofacitinib shows promise in ulcerative colitis

16 August 2012

Positive new data for Pfizer's tofacitinib; possible regulatory delay

1 August 2012

FDA advisory backs Pfizer's tofacitinib for RA

10 May 2012

Ulcerative colitis drug market to reach $3 billion by 2020

2 May 2012

US rheumatologists continue to increase use of biologics for RA treatment

29 March 2012

Unexpectedly strong data for Galapagos rheumatoid arthritis drug candidate

24 November 2011

46% of US dermatologists expect to prescribe Pfizer’s tofacitinib to psoriasis patients who failed one biologic

17 November 2011

Many European dermatologists want more post-marketing data before Rxing Pfizer’s Janus

12 September 2011

Patient death linked to Pfizer’s RA drug candidate tofacitinib

26 April 2011

Pfizer’s tofacitinib meets Ph III endpoints in patients with active RA

7 March 2011

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end